birdflustocks
$ARCT "However, we do have a technology and capabilities that can enable key players in the oncology space. With the recent acquisition of myNEO, we now have capabilities of neoantigen design, and we have clearly a differentiated saRNA platform that is better at engaging T cells, for example, and proven mRNA delivery and manufacturing. For these reasons, of course, we're always open to enabling key players in oncology (...)"
$BNTX
14

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault34.jpg)